Percentage of NPM-mutated cells within sorted fractions of AML
| Sample . | Subtype . | CD34+CD38− . | CD34+CD38+ . | CD3+ . | CD34−CD38+ . |
|---|---|---|---|---|---|
| 1 | A | 5 | 10.4 | 3.5 | 99 |
| 2 | A | 1.7 | 0 | 3.8 | 100 |
| 3 | A | 7.5 | 14 | 0 | 90.5 |
| 4 | A | 3.9 | 60 | 0 | 100 |
| 5 | A | 0 | 1.2 | 8.6 | 100 |
| 6 | A | 0 | 13.8 | 0.2 | 97 |
| 8 | A | 7.3 | 16 | 2.4 | 97 |
| 9 | A | 7.7 | 5 | 2.4 | 100 |
| Mean of subtype A | 4.1 ± 3.3* | 15 ± 19.1 | 2.6 ± 2.9† | 97.9 ± 3.3 | |
| 14 | B | 12.2 | 83 | 1.4 | 100 |
| 15 | B | 16.5 | 100 | ND | 94.9 |
| 16 | B | 7.4 | 45 | 1.4 | 100 |
| Mean of subtype B | 12 ± 4.6* | 76 ± 28.2 | 1.4 | 98.3 ± 2.0 | |
| 20 | C | 94 | 98.7 | 0.3 | 100 |
| Sample . | Subtype . | CD34+CD38− . | CD34+CD38+ . | CD3+ . | CD34−CD38+ . |
|---|---|---|---|---|---|
| 1 | A | 5 | 10.4 | 3.5 | 99 |
| 2 | A | 1.7 | 0 | 3.8 | 100 |
| 3 | A | 7.5 | 14 | 0 | 90.5 |
| 4 | A | 3.9 | 60 | 0 | 100 |
| 5 | A | 0 | 1.2 | 8.6 | 100 |
| 6 | A | 0 | 13.8 | 0.2 | 97 |
| 8 | A | 7.3 | 16 | 2.4 | 97 |
| 9 | A | 7.7 | 5 | 2.4 | 100 |
| Mean of subtype A | 4.1 ± 3.3* | 15 ± 19.1 | 2.6 ± 2.9† | 97.9 ± 3.3 | |
| 14 | B | 12.2 | 83 | 1.4 | 100 |
| 15 | B | 16.5 | 100 | ND | 94.9 |
| 16 | B | 7.4 | 45 | 1.4 | 100 |
| Mean of subtype B | 12 ± 4.6* | 76 ± 28.2 | 1.4 | 98.3 ± 2.0 | |
| 20 | C | 94 | 98.7 | 0.3 | 100 |
The AML sample number is in the first column. The figures are percentages of cells that contain mutated NPM derived from quantitative genomic PCR. ND indicates not done.
The percentage of NPM-mutated cells in the CD34+CD38− cells is significantly lower than in the CD34−CD38+ fraction (P < .001 for subtypes A and B).
There is no significant difference between the percentage of NPM in the CD3+ fraction and the CD34+CD38− (P = .3) or in the CD34+CD38+ (P = .1) fractions of subtype A samples.